AACR: 2020 to 2024 Saw Drop in Number of Unique Lung Cancer Trial Sites

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on April 22, 2026.

via HealthDay

WEDNESDAY, April 22, 2026 -- There was a decrease in the number of unique sites where phase 1 clinical trials for non-small cell lung cancer (NSCLC) were conducted between 2020 and 2024, according to a study presented at the annual meeting of the American Association for Cancer Research, held from April 17 to 22 in San Diego.

Brittany Avin McKelvey, Ph.D., from the LUNGevity Foundation in Bethesda, Maryland, and colleagues analyzed interventional, industry-sponsored clinical trials for NSCLC in early phase 1 or phase 1 opening in January 2020 to December 2024 to assess the distribution of early-phase clinical trial sites.

Within the study period, 555 trials opened at all sites in 47 countries, totaling 8,393 trial instances, defined as the initiation of a unique trial at a unique site; most (45 percent) were located in the United States. The researchers found that the number of trials opening increased until 2024, but there was a decrease in the number of unique trial sites and trial instances both globally and within the United States starting in 2022 and continuing through 2024. During the entire study period, there was a decrease in the number of U.S. sites with at least one trial opening (395 sites in 2020 to 223 sites in 2024). This decrease was not seen for the sites with the highest trial volume (top 20 sites had at least 27 trials open in the study period).

"This analysis demonstrates a concerning trend towards trial consolidation at top performing sites in the U.S., further supporting concerns regarding site saturation and conflicting with appeals to decentralize and move trials into the community," McKelvey said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-23 02:08

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords